TY - JOUR AU - Ribas, A. AU - Hamid, O. AU - Daud, A. AU - Hodi, F. S. AU - Wolchok, J. D. AU - Kefford, R. PY - 2016 DA - 2016// TI - Association of Pembrolizumab with Tumor Response and Survival among Patients with Advanced Melanoma JO - Jama. VL - 315 UR - https://doi.org/10.1001/jama.2016.4059 DO - 10.1001/jama.2016.4059 ID - Ribas2016 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. AU - Dutriaux, C. AU - Maio, M. AU - Mortier, L. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Hodi, F. S. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Grob, J. J. AU - Rutkowski, P. AU - Cowey, C. L. PY - 2018 DA - 2018// TI - Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30700-9 DO - 10.1016/S1470-2045(18)30700-9 ID - Hodi2018 ER - TY - JOUR AU - Wolchok, J. D. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Rutkowski, P. AU - Grob, J. J. AU - Cowey, C. L. PY - 2017 DA - 2017// TI - Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1709684 DO - 10.1056/NEJMoa1709684 ID - Wolchok2017 ER - TY - JOUR AU - Larkin, J. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Grob, J. J. AU - Cowey, C. L. AU - Lao, C. D. PY - 2015 DA - 2015// TI - Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504030 DO - 10.1056/NEJMoa1504030 ID - Larkin2015 ER - TY - JOUR AU - Puzanov, I. AU - Dummer, R. AU - Schachter, J. AU - Pavlick, A. C. AU - Gonzalez, R. AU - Ascierto, P. A. PY - 2015 DA - 2015// TI - Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL) JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/jco.2015.33.15_suppl.3012 DO - 10.1200/jco.2015.33.15_suppl.3012 ID - Puzanov2015 ER - TY - JOUR AU - Weber, J. S. AU - D'Angelo, S. P. AU - Minor, D. AU - Hodi, F. S. AU - Gutzmer, R. AU - Neyns, B. PY - 2015 DA - 2015// TI - Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70076-8 DO - 10.1016/S1470-2045(15)70076-8 ID - Weber2015 ER - TY - JOUR AU - Madore, J. AU - Vilain, R. E. AU - Menzies, A. M. AU - Kakavand, H. AU - Wilmott, J. S. AU - Hyman, J. PY - 2015 DA - 2015// TI - PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials JO - Pigment Cell Melanoma Res VL - 28 UR - https://doi.org/10.1111/pcmr.12340 DO - 10.1111/pcmr.12340 ID - Madore2015 ER - TY - JOUR AU - Tumeh, P. C. AU - Hellmann, M. D. AU - Hamid, O. AU - Tsai, K. K. AU - Loo, K. L. AU - Gubens, M. A. PY - 2017 DA - 2017// TI - Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC JO - Cancer Immunol Res. VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-16-0325 DO - 10.1158/2326-6066.CIR-16-0325 ID - Tumeh2017 ER - TY - JOUR AU - Tumeh, P. C. AU - Harview, C. L. AU - Yearley, J. H. AU - Shintaku, I. P. AU - Taylor, E. J. AU - Robert, L. PY - 2014 DA - 2014// TI - PD-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature. VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER - TY - JOUR AU - Alexandrov, L. B. AU - Nik-Zainal, S. AU - Wedge, D. C. AU - Aparicio, S. A. AU - Behjati, S. AU - Biankin, A. V. PY - 2013 DA - 2013// TI - Signatures of mutational processes in human cancer JO - Nature. VL - 500 UR - https://doi.org/10.1038/nature12477 DO - 10.1038/nature12477 ID - Alexandrov2013 ER - TY - JOUR AU - Allen, E. M. AU - Miao, D. AU - Schilling, B. AU - Shukla, S. A. AU - Blank, C. AU - Zimmer, L. PY - 2015 DA - 2015// TI - Genomic correlates of response to CTLA-4 blockade in metastatic melanoma JO - Science VL - 350 UR - https://doi.org/10.1126/science.aad0095 DO - 10.1126/science.aad0095 ID - Allen2015 ER - TY - JOUR AU - Snyder, A. AU - Makarov, V. AU - Merghoub, T. AU - Yuan, J. AU - Zaretsky, J. M. AU - Desrichard, A. PY - 2014 DA - 2014// TI - Genetic basis for clinical response to CTLA-4 blockade in melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406498 DO - 10.1056/NEJMoa1406498 ID - Snyder2014 ER - TY - JOUR AU - Johnson, D. B. AU - Frampton, G. M. AU - Rioth, M. J. AU - Yusko, E. AU - Xu, Y. AU - Guo, X. PY - 2016 DA - 2016// TI - Targeted next generation sequencing identifies markers of response to PD-1 blockade JO - Cancer Immunol Res VL - 4 UR - https://doi.org/10.1158/2326-6066.CIR-16-0143 DO - 10.1158/2326-6066.CIR-16-0143 ID - Johnson2016 ER - TY - JOUR AU - Goodman, A. M. AU - Kato, S. AU - Bazhenova, L. AU - Patel, S. P. AU - Frampton, G. M. AU - Miller, V. PY - 2017 DA - 2017// TI - Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-17-0386 DO - 10.1158/1535-7163.MCT-17-0386 ID - Goodman2017 ER - TY - JOUR AU - Hugo, W. AU - Zaretsky, J. M. AU - Sun, L. AU - Song, C. AU - Moreno, B. H. AU - Hu-Lieskovan, S. PY - 2016 DA - 2016// TI - Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma JO - Cell. VL - 165 UR - https://doi.org/10.1016/j.cell.2016.02.065 DO - 10.1016/j.cell.2016.02.065 ID - Hugo2016 ER - TY - JOUR AU - Shin, D. S. AU - Zaretsky, J. M. AU - Escuin-Ordinas, H. AU - Garcia-Diaz, A. AU - Hu-Lieskovan, S. AU - Kalbasi, A. PY - 2017 DA - 2017// TI - Primary resistance to PD-1 blockade mediated by JAK1/2 mutations JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-1223 DO - 10.1158/2159-8290.CD-16-1223 ID - Shin2017 ER - TY - JOUR AU - Roh, W. AU - Chen, P. L. AU - Reuben, A. AU - Spencer, C. N. AU - Prieto, P. A. AU - Miller, J. P. PY - 2017 DA - 2017// TI - Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance JO - Sci Transl Med VL - 9 UR - https://doi.org/10.1126/scitranslmed.aah3560 DO - 10.1126/scitranslmed.aah3560 ID - Roh2017 ER - TY - JOUR AU - Samstein, R. M. AU - Lee, C. H. AU - Shoushtari, A. N. AU - Hellmann, M. D. AU - Shen, R. AU - Janjigian, Y. Y. PY - 2019 DA - 2019// TI - Tumor mutational load predicts survival after immunotherapy across multiple cancer types JO - Nat Genet VL - 51 UR - https://doi.org/10.1038/s41588-018-0312-8 DO - 10.1038/s41588-018-0312-8 ID - Samstein2019 ER - TY - JOUR AU - Lee, J. H. AU - Long, G. V. AU - Boyd, S. AU - Lo, S. AU - Menzies, A. M. AU - Tembe, V. PY - 2017 DA - 2017// TI - Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx026 DO - 10.1093/annonc/mdx026 ID - Lee2017 ER - TY - JOUR AU - Rowe, S. P. AU - Luber, B. AU - Makell, M. AU - Brothers, P. AU - Santmyer, J. AU - Schollenberger, M. D. PY - 2018 DA - 2018// TI - From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting JO - Mol Oncol VL - 12 UR - https://doi.org/10.1002/1878-0261.12373 DO - 10.1002/1878-0261.12373 ID - Rowe2018 ER - TY - JOUR AU - Herbreteau, G. AU - Vallee, A. AU - Knol, A. C. AU - Theoleyre, S. AU - Quereux, G. AU - Varey, E. PY - 2018 DA - 2018// TI - Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy JO - Oncotarget. VL - 9 UR - https://doi.org/10.18632/oncotarget.25404 DO - 10.18632/oncotarget.25404 ID - Herbreteau2018 ER - TY - JOUR AU - Buchhalter, I. AU - Rempel, E. AU - Endris, V. AU - Allgauer, M. AU - Neumann, O. AU - Volckmar, A. L. PY - 2018 DA - 2018// TI - Size matters: dissecting key parameters for panel-based tumor mutational burden (TMB) analysis JO - Int J Cancer VL - 144 UR - https://doi.org/10.1002/ijc.31878 DO - 10.1002/ijc.31878 ID - Buchhalter2018 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur Journal Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Kent, W. J. AU - Sugnet, C. W. AU - Furey, T. S. AU - Roskin, K. M. AU - Pringle, T. H. AU - Zahler, A. M. PY - 2002 DA - 2002// TI - The human genome browser at UCSC JO - Genome Res VL - 12 UR - https://doi.org/10.1101/gr.229102 DO - 10.1101/gr.229102 ID - Kent2002 ER - TY - JOUR AU - Altschul, S. F. AU - Madden, T. L. AU - Schaffer, A. A. AU - Zhang, J. AU - Zhang, Z. AU - Miller, W. PY - 1997 DA - 1997// TI - Gapped BLAST and PSI-BLAST: a new generation of protein database search programs JO - Nucleic Acids Res VL - 25 UR - https://doi.org/10.1093/nar/25.17.3389 DO - 10.1093/nar/25.17.3389 ID - Altschul1997 ER - TY - JOUR AU - Whale, A. S. AU - Devonshire, A. S. AU - Karlin-Neumann, G. AU - Regan, J. AU - Javier, L. AU - Cowen, S. PY - 2017 DA - 2017// TI - International Interlaboratory digital PCR study demonstrating high reproducibility for the measurement of a rare sequence variant JO - Anal Chem VL - 89 UR - https://doi.org/10.1021/acs.analchem.6b03980 DO - 10.1021/acs.analchem.6b03980 ID - Whale2017 ER - TY - JOUR AU - Huggett, J. F. AU - Foy, C. A. AU - Benes, V. AU - Emslie, K. AU - Garson, J. A. AU - Haynes, R. PY - 2013 DA - 2013// TI - The digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments JO - Clin Chem VL - 59 UR - https://doi.org/10.1373/clinchem.2013.206375 DO - 10.1373/clinchem.2013.206375 ID - Huggett2013 ER - TY - JOUR AU - Chalmers, Z. R. AU - Connelly, C. F. AU - Fabrizio, D. AU - Gay, L. AU - Ali, S. M. AU - Ennis, R. PY - 2017 DA - 2017// TI - Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden JO - Genome Med VL - 9 UR - https://doi.org/10.1186/s13073-017-0424-2 DO - 10.1186/s13073-017-0424-2 ID - Chalmers2017 ER - TY - JOUR AU - Spindler, K. L. AU - Appelt, A. L. AU - Pallisgaard, N. AU - Andersen, R. F. AU - Brandslund, I. AU - Jakobsen, A. PY - 2014 DA - 2014// TI - Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer JO - Int J Cancer VL - 135 UR - https://doi.org/10.1002/ijc.28946 DO - 10.1002/ijc.28946 ID - Spindler2014 ER - TY - JOUR AU - Lyu, G. Y. AU - Yeh, Y. H. AU - Yeh, Y. C. AU - Wang, Y. C. PY - 2018 DA - 2018// TI - Mutation load estimation model as a predictor of the response to cancer immunotherapy JO - NPJ Genom Med VL - 3 UR - https://doi.org/10.1038/s41525-018-0051-x DO - 10.1038/s41525-018-0051-x ID - Lyu2018 ER - TY - JOUR AU - Ashida, A. AU - Sakaizawa, K. AU - Uhara, H. AU - Okuyama, R. PY - 2017 DA - 2017// TI - Circulating tumour DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients JO - Acta Derm Venereol VL - 97 UR - https://doi.org/10.2340/00015555-2748 DO - 10.2340/00015555-2748 ID - Ashida2017 ER - TY - JOUR AU - Zehir, A. AU - Benayed, R. AU - Shah, R. H. AU - Syed, A. AU - Middha, S. AU - Kim, H. R. PY - 2017 DA - 2017// TI - Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients JO - Nat Med VL - 23 UR - https://doi.org/10.1038/nm.4333 DO - 10.1038/nm.4333 ID - Zehir2017 ER - TY - JOUR AU - Hayward, N. K. AU - Wilmott, J. S. AU - Waddell, N. AU - Johansson, P. A. AU - Field, M. A. AU - Nones, K. PY - 2017 DA - 2017// TI - Whole-genome landscapes of major melanoma subtypes JO - Nature. VL - 545 UR - https://doi.org/10.1038/nature22071 DO - 10.1038/nature22071 ID - Hayward2017 ER - TY - JOUR AU - Furney, S. J. AU - Turajlic, S. AU - Stamp, G. AU - Thomas, J. M. AU - Hayes, A. AU - Strauss, D. PY - 2014 DA - 2014// TI - The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis JO - Pigment Cell Melanoma Res VL - 27 UR - https://doi.org/10.1111/pcmr.12279 DO - 10.1111/pcmr.12279 ID - Furney2014 ER - TY - JOUR AU - Furney, S. J. AU - Turajlic, S. AU - Stamp, G. AU - Nohadani, M. AU - Carlisle, A. AU - Thomas, J. M. PY - 2013 DA - 2013// TI - Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma JO - J Pathol VL - 230 UR - https://doi.org/10.1002/path.4204 DO - 10.1002/path.4204 ID - Furney2013 ER - TY - JOUR AU - Matsushita, H. AU - Vesely, M. D. AU - Koboldt, D. C. AU - Rickert, C. G. AU - Uppaluri, R. AU - Magrini, V. J. PY - 2012 DA - 2012// TI - Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting JO - Nature. VL - 482 UR - https://doi.org/10.1038/nature10755 DO - 10.1038/nature10755 ID - Matsushita2012 ER - TY - JOUR AU - Riaz, N. AU - Morris, L. AU - Havel, J. J. AU - Makarov, V. AU - Desrichard, A. AU - Chan, T. A. PY - 2016 DA - 2016// TI - The role of neoantigens in response to immune checkpoint blockade JO - Int Immunol VL - 28 UR - https://doi.org/10.1093/intimm/dxw019 DO - 10.1093/intimm/dxw019 ID - Riaz2016 ER - TY - JOUR AU - Hellmann, M. D. AU - Callahan, M. K. AU - Awad, M. M. AU - Calvo, E. AU - Ascierto, P. A. AU - Atmaca, A. PY - 2018 DA - 2018// TI - Tumor mutational burden and efficacy of Nivolumab monotherapy and in combination with Ipilimumab in small-cell lung Cancer JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.04.001 DO - 10.1016/j.ccell.2018.04.001 ID - Hellmann2018 ER - TY - JOUR AU - Morrison, C. AU - Pabla, S. AU - Conroy, J. M. AU - Nesline, M. K. AU - Glenn, S. T. AU - Dressman, D. PY - 2018 DA - 2018// TI - Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0344-8 DO - 10.1186/s40425-018-0344-8 ID - Morrison2018 ER - TY - JOUR AU - Gangadhar, T. C. AU - Savitch, S. L. AU - Yee, S. S. AU - Xu, W. AU - Huang, A. C. AU - Harmon, S. PY - 2018 DA - 2018// TI - Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma JO - Pigment Cell Melanoma Res VL - 31 UR - https://doi.org/10.1111/pcmr.12623 DO - 10.1111/pcmr.12623 ID - Gangadhar2018 ER - TY - JOUR AU - Seith, F. AU - Forschner, A. AU - Schmidt, H. AU - Pfannenberg, C. AU - Guckel, B. AU - Nikolaou, K. PY - 2018 DA - 2018// TI - 18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start JO - Eur J Nucl Med Mol Imaging VL - 45 UR - https://doi.org/10.1007/s00259-017-3813-2 DO - 10.1007/s00259-017-3813-2 ID - Seith2018 ER - TY - JOUR AU - Conforti, F. AU - Pala, L. AU - Bagnardi, V. AU - Pas, T. AU - Martinetti, M. AU - Viale, G. PY - 2018 DA - 2018// TI - Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30261-4 DO - 10.1016/S1470-2045(18)30261-4 ID - Conforti2018 ER - TY - JOUR AU - Gupta, S. AU - Artomov, M. AU - Goggins, W. AU - Daly, M. AU - Tsao, H. PY - 2015 DA - 2015// TI - Gender disparity and mutation burden in metastatic melanoma JO - J Natl Cancer Inst VL - 107 UR - https://doi.org/10.1093/jnci/djv221 DO - 10.1093/jnci/djv221 ID - Gupta2015 ER - TY - JOUR AU - Xiao, D. AU - Pan, H. AU - Li, F. AU - Wu, K. AU - Zhang, X. AU - He, J. PY - 2016 DA - 2016// TI - Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.8213 DO - 10.18632/oncotarget.8213 ID - Xiao2016 ER - TY - JOUR AU - Nosrati, A. AU - Tsai, K. K. AU - Goldinger, S. M. AU - Tumeh, P. AU - Grimes, B. AU - Loo, K. PY - 2017 DA - 2017// TI - Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy JO - Br J Cancer VL - 116 UR - https://doi.org/10.1038/bjc.2017.70 DO - 10.1038/bjc.2017.70 ID - Nosrati2017 ER - TY - JOUR AU - Joseph, R. W. AU - Elassaiss-Schaap, J. AU - Kefford, R. AU - Hwu, W. J. AU - Wolchok, J. D. AU - Joshua, A. M. PY - 2018 DA - 2018// TI - Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with Pembrolizumab JO - Clin Cancer Res VL - 24 ID - Joseph2018 ER - TY - JOUR AU - Shi, W. AU - Ng, C. K. Y. AU - Lim, R. S. AU - Jiang, T. AU - Kumar, S. AU - Li, X. PY - 2018 DA - 2018// TI - Reliability of whole-exome sequencing for assessing Intratumor genetic heterogeneity JO - Cell Rep VL - 25 UR - https://doi.org/10.1016/j.celrep.2018.10.046 DO - 10.1016/j.celrep.2018.10.046 ID - Shi2018 ER - TY - JOUR AU - Lee, J. H. J. AU - Lyle, M. AU - Menzies, A. M. AU - Chan, M. M. K. AU - Lo, S. AU - Clements, A. PY - 2018 DA - 2018// TI - Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma JO - Pigment Cell Melanoma Res VL - 31 UR - https://doi.org/10.1111/pcmr.12675 DO - 10.1111/pcmr.12675 ID - Lee2018 ER -